R&D,Clinical Development,Weekly Roundups,Biology

Weekly News Round-up – 26/2/21

2 months ago By Josh Neil
  • Share on

  • Facebook
  • Linkedin
Proventa International Weekly News

In the news this week, Moderna is set to make a profit for the first time with huge profit expectations for 2021. In other news, Icon acquires PRA for $12 billion to create a ‘mega-CRO’, and the first variant of the South African COVID variant specifically is shipped for trials.

MODERNA FORECASTS $18 BILLION IN VACCINE SALES FOR 2021 – Moderna has announced an expected $18.4 billion in profit from its coronavirus vaccine in 2021, much higher than the $11.2 billion predicted by analysts. This figure would give the company a profit for the first time. This number could also rise further given Moderna’s current discussions with governments about distributing the COVID vaccine worldwide. 

ICON ACQUIRES PRA IN $12 BILLION DEAL – Contract R&D company Icon has announced the acquisition of competitor PRA Health Services for around $12 billion. The acquisition will create a ‘mega-CRO’. This will have partnerships already cemented with a number of major pharma organisations. Icon claimed the merger would create a company with a top spot in several key markets. 

MODERNA SHIPS SOUTH AFRICA VARIANT VACCINE CANDIDATES OFF TO TRIALS –  Moderna has sent several doses of its vaccine candidate designed to combat the South African variant of COVID-19 to the US National Institutes of Health (NIH). Manufacturing of clinical trial material for the candidate has also been completed, it announced. In addition to this phase 1 study, the company is evaluating booster doses of its current vaccine, to increase neutralising immunity against high-risk variants of the virus.

In other news:

Clinical
FDA set to approve J&J’s one-shot COVID vaccine for emergency use
Sanofi’s immunotherapy drug Libtayo receives regulatory approval in first line lung cancer

Manufacturing
Australia could follow US in approving Pfizer vaccine for standard cold storage
UK COVID vaccine numbers drop by a third as supply slows

That’s all for now. See you next week!

Joshua Neil, Editor
Proventa International

More news

Preclinical Pharmacokinetics: Solving the Problems of Early-Stage Predictive Assays

Understanding the pharmacokinetic profile (PK) of a compound is critical in selecting appropriate drug candidates in preclinical studies. The challenge is to predict the PKs of compounds in humans using early-stage predictive assays in these studies. Innovations in the last...

22 hours ago
R&D,Clinical Development,Weekly Roundups,Biology

Preclinical Pharmacokinetics: Solving the Problems of Early-Stage Predictive Assays

Understanding the pharmacokinetic profile (PK) of a compound is critical in selecting appropriate drug candidates in preclinical studies. The challenge is to predict the PKs of compounds in humans using early-stage predictive assays in these studies. Innovations in the last...

22 hours ago

Emerging therapeutic areas of clinical attention & investment opportunities

Investment opportunities have changed substantially across the life sciences and pharmaceutical industry in the last ten years. It has become obvious that areas like neuroscience and respiratory medicine require additional support due to unmet clinical needs. Investment is key to...

4 days ago
R&D,Clinical Development,Weekly Roundups,Biology

Emerging therapeutic areas of clinical attention & investment opportunities

Investment opportunities have changed substantially across the life sciences and pharmaceutical industry in the last ten years. It has become obvious that areas like neuroscience and respiratory medicine require additional support due to unmet clinical needs. Investment is key to...

4 days ago

Weekly News Round-up – 16/4/21

In the news this week, Johnson & Johnson’s (J&J’s) COVID-19 vaccine rollout in Europe halted following blood clot concerns in the U.S. In other news, a biopharma partnership aims to expedite drug development in immunology, and research reveals substantial public...

4 days ago
R&D,Clinical Development,Weekly Roundups,Biology

Weekly News Round-up – 16/4/21

In the news this week, Johnson & Johnson’s (J&J’s) COVID-19 vaccine rollout in Europe halted following blood clot concerns in the U.S. In other news, a biopharma partnership aims to expedite drug development in immunology, and research reveals substantial public...

4 days ago
Working With us

Interested?
Reserve your space